Expression profile-based screening for critical genes reveals S100A4, ACKR3 and CDH1 in docetaxel-resistant prostate cancer cells

Docetaxel is a first-line anticancer drug widely used in the treatment of advanced prostate cancer. However, its therapeutic efficacy is limited by its side effects and the development of chemoresistance by the tumor. Using a gene differential expression microarray, we identified 449 genes different...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Sha, Min, Zhixue, Qiao, Xianli, Chen, Shengxian, Yang, Jian, Zhang, Xiao, Liu, Xigang, Ran, Weijie, Lv, Renguang, Lin, Ying, Wang, Jin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals 2019
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6949054/
https://www.ncbi.nlm.nih.gov/pubmed/31895690
http://dx.doi.org/10.18632/aging.102600

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6949054/
https://www.ncbi.nlm.nih.gov/pubmed/31895690
http://dx.doi.org/10.18632/aging.102600

Ejemplares similares